Literature DB >> 1381130

Testicular sex cord-stromal lesions: immunohistochemical analysis of cytokeratin, vimentin and steroidogenic enzymes.

H Sasano1, N Nakashima, O Matsuzaki, H Kato, S Aizawa, N Sasano, H Nagura.   

Abstract

We have studied immunolocalization of all steroidogenic enzyme involved in sex steroids biosynthesis, P-450 side chain cleavage (P-450scc), 3 beta hydroxy steroid dehydrogenase (3 beta-HSD), P-450 17 alpha hydroxylase (P-450(17 alpha)) and P-450 aromatase (P-450arom) and that of vimentin and cytokeratin in 14 cases of testicular sex cord-stromal tumours (6 Leydig cell tumours, 5 Sertoli cell tumours, 2 fibromas and 1 granulosa cell tumour) as well as 4 cases of hyperplasia (2 Leydig and 2 Sertoli). Leydig cell tumour expressed all four steroidogenic enzymes examined, indicating that this tumour can synthesize oestrogen from cholesterol. In 2 cases of Sertoli cell tumour, the tumour cells with clear cytoplasm and without Reinke's crystals expressed P-450ssc, 3 beta-HSD and P-450(17 alpha), suggesting the capability of androgen production in these tumour cells. Fibromas and granulosa cell tumour were negative for the enzymes examined. In immunohistochemistry of intermediate filaments, Leydig cell tumours demonstrated only vimentin. Sertoli cells in hyperplasia and non-neoplastic testis expressed only vimentin but Sertoli cell tumours expressed both cytokeratin and vimentin. Cytokeratin immunoreactivity was correlated with morphological epithelial differentiation in Sertoli cell tumour. These findings in testicular Sertoli cell tumour are considered to represent the multiple differentiation capacity of this neoplasm. Immunohistochemical study of steroidogenic enzymes and intermediate filaments provided new insight into neoplastic steroidogenesis and the differentiation capacity of testicular sex cord-stromal neoplasms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381130     DOI: 10.1007/bf01607050

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  30 in total

1.  Intermediate filaments cytokeratin and vimentin in ovarian sex cord-stromal tumours with correlative studies in adult and fetal ovaries.

Authors:  E Benjamin; S Law; L G Bobrow
Journal:  J Pathol       Date:  1987-08       Impact factor: 7.996

2.  Intermediate-sized filaments present in Sertoli cells are of the vimentin type.

Authors:  W W Franke; C Grund; E Schmid
Journal:  Eur J Cell Biol       Date:  1979-08       Impact factor: 4.492

3.  Unusual gonadal stromal tumor of the testis. Case report with ultrastructural observations.

Authors:  H L Evans
Journal:  Arch Pathol Lab Med       Date:  1977-06       Impact factor: 5.534

4.  Immunolocalization of 3 beta-hydroxysteroid dehydrogenase in human ovary.

Authors:  H Sasano; T Mori; N Sasano; H Nagura; J I Mason
Journal:  J Reprod Fertil       Date:  1990-07

Review 5.  Contributions of immunocytochemistry to the diagnosis and study of ovarian neoplasms.

Authors:  R J Kurman; P Ganjei; M Nadji
Journal:  Int J Gynecol Pathol       Date:  1984       Impact factor: 2.762

6.  Immunohistochemical analysis for desmin in normal and neoplastic ovarian stromal tissue.

Authors:  D Lastarria; R K Sachdev; R A Babury; H M Yu; G J Nuovo
Journal:  Arch Pathol Lab Med       Date:  1990-05       Impact factor: 5.534

7.  Immunohistochemical studies of steroidogenic enzymes (aromatase, 17 alpha-hydroxylase and cholesterol side-chain cleavage cytochromes P-450) in sex cord-stromal tumors of the ovary.

Authors:  H Sasano; M Okamoto; J I Mason; E R Simpson; C R Mendelson; N Sasano; S G Silverberg
Journal:  Hum Pathol       Date:  1989-05       Impact factor: 3.466

8.  Testicular stromal tumor with myofilaments: ultrastructural comparison with normal gonadal stroma.

Authors:  M A Greco; H D Feiner; K S Theil; A A Mufarrij
Journal:  Hum Pathol       Date:  1984-03       Impact factor: 3.466

9.  An immunohistological study of steroid localization in Sertoli-Leydig tumors of the ovary and testis.

Authors:  R J Kurman; D Andrade; U Goebelsmann; C R Taylor
Journal:  Cancer       Date:  1978-10       Impact factor: 6.860

10.  Ovarian heterologous Sertoli-Leydig cell tumors with gastrointestinal-type epithelium. An immunohistochemical analysis.

Authors:  P Aguirre; R E Scully; R A DeLellis
Journal:  Arch Pathol Lab Med       Date:  1986-06       Impact factor: 5.534

View more
  6 in total

1.  Testicular juvenile granulosa cell and Sertoli cell tumours: a clinicopathological study of 29 cases from the Kiel Paediatric Tumour Registry.

Authors:  D Harms; L R Kock
Journal:  Virchows Arch       Date:  1997-04       Impact factor: 4.064

2.  Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies.

Authors:  K Watanabe; H Sasano; N Harada; M Ozaki; H Niikura; S Sato; A Yajima
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

3.  Sex cord tumour of the adult testis.

Authors:  Ismail Türker Köksal; Mustafa Usta; Akif Ciftcioglu; Tibet Erdogru; Erdal Kukul; Mehmet Baykara
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

4.  Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour.

Authors:  Anne Hege Straume; Kristian Løvås; Hrvoje Miletic; Karsten Gravdal; Per Eystein Lønning; Stian Knappskog
Journal:  Eur J Endocrinol       Date:  2012-02-01       Impact factor: 6.664

Review 5.  Adult-type granulosa cell tumour of the testis: Report of a case and review of the literature.

Authors:  Osama Al-Alao; Tawiz Gul; Ammar Al-Ani; Issam A Bozom; Khalid Al-Jalham
Journal:  Arab J Urol       Date:  2016-02-06

Review 6.  Adult type granulosa cell tumor of the testis with a heterologous sarcomatous component: case report and review of the literature.

Authors:  Thomas E O Schubert; Robert Stoehr; Arndt Hartmann; Sabrina Schöne; Mathias Löbelenz; Gregor Mikuz
Journal:  Diagn Pathol       Date:  2014-06-03       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.